Business Context and Reporting Period
Tenax Therapeutics, Inc. is a development-stage specialty pharmaceutical company focused on cardiovascular and pulmonary diseases. This unaudited Form 10-Q covers the quarter ended March 31, 2020. Its lead candidate, levosimendan, is being studied for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF); the company reported no product revenue.
Financial Performance and Liquidity
| Metric | Q1 2020 | Q1 2019 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Operating expenses | $2.665 million | $1.662 million, up 60% |
| Research and development | $1.343 million | $0.483 million, up 178% |
| General and administrative | $1.323 million | $1.179 million, up 12% |
| Net loss | $2.655 million; $0.38 per share | $1.617 million; $0.33 per share |
| Operating cash used | $2.671 million | $2.133 million |
| Cash and cash equivalents | $4.359 million at March 31 | $4.906 million at December 31, 2019 |
| Marketable securities | $0.499 million | $0.494 million at December 31, 2019 |
| Working capital | $3.293 million | $3.648 million at December 31, 2019 |
There is no meaningful operating margin to report because the filing reports no revenue. Total assets were $5.955 million and total liabilities were $2.536 million at March 31, 2020. Liabilities included $145,000 in operating lease obligations; the filing reports no material interest-bearing debt at quarter-end. Accumulated deficit was $238.823 million. The company raised approximately $2.13 million net in a March offering of common stock and pre-funded warrants.
Material Changes Versus the Prior Comparable Period
Net loss increased approximately 64% year over year, principally as R&D spending rose with Phase 2 HELP Study activity. Clinical and preclinical development costs increased about $863,000, including higher CRO and enrolled-patient costs. Operating cash use rose approximately $538,000. Financing cash inflow increased to $2.13 million from $97,000, mainly due to the March offering. Basic and diluted weighted-average shares increased to 6.974 million from 4.887 million.
Outlook, Risks, Contingencies, and Unusual Items
- Funding and going concern: Management said existing resources were expected to fund planned operations through the third quarter of 2020, but substantial additional financing would be required thereafter. The filing states that substantial doubt exists about the company’s ability to continue as a going concern. Further financing may dilute shareholders, impose debt covenants, or require licensing rights on unfavorable terms.
- Clinical program: Enrollment in the Phase 2 HELP Study was completed in March 2020; primary-endpoint results depend on unblinding. Preliminary, investigator-reported open-label lead-in data showed approximately 84% of patients met responder criteria, with reported improvements in exercise hemodynamics. These findings are preliminary, not the blinded primary-endpoint results.
- COVID-19: The company warned that the pandemic could disrupt trial sites, recruitment, protocol compliance, CRO and manufacturing operations, and regulatory review, potentially delaying trial results and development.
- Orion arbitration: Orion disputed whether its oral levosimendan formulation falls under license line-extension provisions. The hearing took place April 7–8, 2020, with a final award expected by May 31, 2020. The filing does not state the award outcome.
- Subsequent PPP loan: On April 30, 2020, the company received a $244,657 loan at 1% interest, with a two-year term and payments scheduled to begin December 30, 2020, subject to potential forgiveness. Forgiveness is uncertain; the company also disclosed eligibility, audit, repayment, penalty, and reputational risks.
- Nasdaq listing: The company received an April 24 notice that its share price had been below the $1 minimum bid for 30 consecutive business days. The stated cure deadline was December 28, 2020; failure to regain compliance could lead to delisting.
- Other: The company said disclosure controls and procedures were effective as of March 31, 2020, and reported no material changes in internal control or material pending legal proceedings.
Most Important Facts for Investors to Verify
- Whether additional financing was secured in time to address the stated post-Q3 2020 funding need and going-concern uncertainty.
- The unblinded HELP Study primary-endpoint results, their timing, and any effect of COVID-19 on follow-up or reporting.
- The outcome and implications of the Orion arbitration.
- Whether the PPP loan was forgiven and whether any eligibility review, repayment, or other consequences followed.
- Whether Tenax regained Nasdaq’s minimum-bid compliance before the stated deadline.
- The extent of dilution from outstanding warrants and pre-funded warrants; the filing reported 14.362 million warrants outstanding at March 31, 2020.